NANCY AGUILERA: Open Payments
NPI 1528631181 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$690 in 31 payments from 12 companies in 2025. Trend: 2023 $138 · 2024 $530 · 2025 $690
Food & beverage: $690
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $169 |
| BridgeBio Pharma, Inc. | 3 | $115 |
| Merck Sharp & Dohme LLC | 4 | $80 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $68 |
| PFIZER INC. | 2 | $53 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $38 |
| Edwards Lifesciences Corporation | 1 | $24 |
| SCPHARMACEUTICALS INC. | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
Products named: Attruby, Wegovy, VERQUVO, JARDIANCE, DUPIXENT, Ozempic, VELSIPITY, LifeVest.
Industry payments across TX — which companies pay providers there.
